Literature DB >> 22384990

Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues.

John F Valliere-Douglass1, William A McFee, Oscar Salas-Solano.   

Abstract

We present here a method for the rapid determination of the intact mass of noncovalently associated antibody heavy chains (HC) and light chains (LC) which result from the attachment of drug conjugates to interchain cysteine residues. By analyzing the antibody-drug conjugate (ADC) using native desalting conditions, we maintain the intact bivalent structure of the ADC, which ordinarily would decompose as a consequence of denaturing chromatographic conditions typically used for liquid chromatographic-mass spectrometric (LC-MS) analysis. The mass of the desalted ADC is subsequently determined using standard desolvation and ionization conditions. Methods presented previously in the literature for analyzing interchain cysteinyl-linked ADCs are either not amenable to online mass spectrometry or result in the denaturing dissociation of conjugated HC and LC during chromatographic separation and subsequent mass measurement. We have avoided this outcome with our method and have successfully and routinely obtained intact mass measurement of IgG1 mAbs conjugated with maleimidocaproyl-monomethyl Auristatin F (mcMMAF) and valine-citrulline-monomethyl Auristatin E (vcMMAE) at interchain cysteine residues. Our results thus represent the first reported direct measurement of the intact mass of an ADC conjugated at interchain cysteine residues.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22384990     DOI: 10.1021/ac203346c

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  26 in total

Review 1.  Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.

Authors:  Jessica R McCombs; Shawn C Owen
Journal:  AAPS J       Date:  2015-01-22       Impact factor: 4.009

2.  Quantitative collision-induced unfolding differentiates model antibody-drug conjugates.

Authors:  Yuwei Tian; Jennifer L Lippens; Chawita Netirojjanakul; Iain D G Campuzano; Brandon T Ruotolo
Journal:  Protein Sci       Date:  2018-12-22       Impact factor: 6.725

Review 3.  Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry.

Authors:  Bo An; Ming Zhang; Jun Qu
Journal:  Drug Metab Dispos       Date:  2014-09-02       Impact factor: 3.922

4.  Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry.

Authors:  Sara Rosati; Yang Yang; Arjan Barendregt; Albert J R Heck
Journal:  Nat Protoc       Date:  2014-03-27       Impact factor: 13.491

5.  Site-specific glycan-conjugated NISTmAb antibody drug conjugate mimetics: synthesis, characterization, and utility.

Authors:  Brian Agnew; Shanhua Lin; Terry Zhang; Robert Aggeler; Trina Mouchahoir; John Schiel
Journal:  Anal Bioanal Chem       Date:  2021-07-06       Impact factor: 4.142

6.  Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.

Authors:  Christopher R Behrens; Edward H Ha; Lawrence L Chinn; Simeon Bowers; Gary Probst; Maureen Fitch-Bruhns; Jorge Monteon; Amanda Valdiosera; Abel Bermudez; Sindy Liao-Chan; Tiffany Wong; Jonathan Melnick; Jan-Willem Theunissen; Mark R Flory; Derrick Houser; Kristy Venstrom; Zoia Levashova; Paul Sauer; Thi-Sau Migone; Edward H van der Horst; Randall L Halcomb; David Y Jackson
Journal:  Mol Pharm       Date:  2015-10-02       Impact factor: 4.939

Review 7.  Challenges and new frontiers in analytical characterization of antibody-drug conjugates.

Authors:  Anil Wagh; Hangtian Song; Ming Zeng; Li Tao; Tapan K Das
Journal:  MAbs       Date:  2018-01-05       Impact factor: 5.857

Review 8.  Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.

Authors:  Olga V Friese; Jacquelynn N Smith; Paul W Brown; Jason C Rouse
Journal:  MAbs       Date:  2018-02-20       Impact factor: 5.857

9.  Mass spectrometry-guided optimization and characterization of a biologically active transferrin-lysozyme model drug conjugate.

Authors:  Son N Nguyen; Cedric E Bobst; Igor A Kaltashov
Journal:  Mol Pharm       Date:  2013-04-10       Impact factor: 4.939

10.  A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.

Authors:  Brendan Bender; Douglas D Leipold; Keyang Xu; Ben-Quan Shen; Jay Tibbitts; Lena E Friberg
Journal:  AAPS J       Date:  2014-06-11       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.